Research and development expenses rose 68.8% year-over-year in Q2 2025, reflecting ongoing clinical trial spending, while revenue remained at zero. Protara ended the quarter with $145.6 million in ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.